.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX07_Enfuvirtide.Enfuvirtide .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX07_Enfuvirtide.Enfuvirtide| name: | Enfuvirtide |
| ATC code: | J05AX07 | route: | subcutaneous |
| n-compartments | 1 |
Enfuvirtide is a synthetic 36-amino acid peptide and a fusion inhibitor antiretroviral drug used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is approved for use in combination with other antiretrovirals for patients experiencing treatment failure or resistance. Enfuvirtide is administered by subcutaneous injection.
Pharmacokinetic parameters in HIV-1 infected adult patients after subcutaneous injection. Data based on steady state following twice daily 90 mg dosing.
Zhang, X, et al., & Patel, I (2007). Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. Journal of clinical pharmacology 47(4) 510–517. DOI:10.1177/0091270006299089 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17389560
Soy, D, et al., & Sheiner, LB (2003). Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clinical pharmacology and therapeutics 74(6) 569–580. DOI:10.1016/j.clpt.2003.09.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14663459
Mould, DR, et al., & Patel, IH (2005). Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clinical pharmacology and therapeutics 77(6) 515–528. DOI:10.1016/j.clpt.2005.02.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15961983